Supernus Pharmaceuticals SUPN Other — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's other — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's other — total revenues?
- Supernus Pharmaceuticals (SUPN) reported other — total revenues of $4.67M in Q1 2026.
- How has Supernus Pharmaceuticals's other — total revenues changed year-over-year?
- Supernus Pharmaceuticals's other — total revenues decreased by 45.6% year-over-year, from $8.58M to $4.67M.
- What is the long-term trend for Supernus Pharmaceuticals's other — total revenues?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's other — total revenues has grown at a -5.0% compound annual growth rate (CAGR), from $33.09M to $26.91M.
- What does other — total revenues mean?
- This metric represents the total gross revenue generated by the company's non-core or miscellaneous business segments that fall outside of its primary therapeutic focus areas. It captures the financial contribution of ancillary products or services that do not constitute the main revenue drivers for the organization. Monitoring this figure helps investors assess the performance and stability of secondary revenue streams within the broader corporate portfolio.